CTOs on the Move

Satsuma Pharmaceuticals

www.satsumarx.com

 
Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.satsumarx.com
  • 395 Oyster Point Boulevard Suite 300
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Satsuma Pharmaceuticals raised $62M on 04/24/2019
Satsuma Pharmaceuticals raised $80M on 03/01/2021

Similar Companies

Medsite

Medsite is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TTG Imaging Solutions

Your partner for nuclear medicine and molecular imaging solutions.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.

Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea`s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea`s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company`s pipeline through global partnering and commercialization efforts.

T Ray Science

Company ProfileVerisante Technology, Inc (Formerly T-Ray Science) is a medical device company committed to developing innovative systems for the early detection of cancer.